Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Patients with nephrotic syndrome were far more likely than healthy controls to suffer end-stage kidney disease, particularly if they had focal segmental glomerulosclerosis or membranous nephropathy.

Idiopathic nephrotic syndrome is the most common disorder of glomerular function in pediatrics. [1] Approximately 40% of children diagnosed with idiopathic nephrotic syndrome will have a relapsing ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically ...

The randomized, open-label INSHORE trial (ClinicalTrials.gov Identifier: NCT05627557) evaluated the safety and efficacy of obinutuzumab in children and young adults in clinical remission aged 2 to 25 ...

For very young children with nephrotic syndrome, longer initial treatment with prednisone didn't offer much benefit, a researcher reported. In a randomized controlled trial of 172 patients ages 1 to 4 ...

DelveInsight's comprehensive analysis reveals the Nephrotic Syndrome therapeutics market reached USD 401 million in 2022 across the 7MM, with emerging therapies including FDA-approved Furoscix and ...

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...